论文部分内容阅读
目的探讨聚ADP核糖聚合酶-1(PARP-1)在乳腺癌组织中的表达及其与临床特征的关系。方法采用免疫组化方法检测58例乳腺癌和11例乳腺良性疾病石蜡包埋标本中PARP-1的表达情况,分析乳腺癌与乳腺良性疾病组织中两者表达差异及乳腺癌组织中PARP-1的阳性表达与临床参数(患者年龄、术后病理分期、肿瘤体积的大小、淋巴结转移状况等指标)的相关性。结果乳腺癌组织中PARP-1的阳性表达率(63.79%)显著高于乳腺良性疾病的阳性表达率(9.09%),P=0.01,乳腺癌标本中有淋巴结转移者的PARP-1阳性表达率(80.00%)高于无淋巴结转移者(51.52%),P=0.031。结论 PARP-1在乳腺癌组织中的表达与淋巴结转移状况有关。PARP-1表达上调可能与乳腺癌的恶性生物学特性有关,从而对乳腺癌的临床诊疗及预后的判断具有一定临床价值。
Objective To investigate the expression of poly ADP-ribose polymerase-1 (PARP-1) in breast cancer and its relationship with clinical features. Methods Immunohistochemistry was used to detect the expression of PARP-1 in 58 cases of breast cancer and 11 cases of benign breast disease. The expressions of PARP-1 in breast cancer and benign breast diseases were analyzed. The correlation between the positive expression and the clinical parameters (patient’s age, postoperative pathological staging, the size of tumor volume, lymph node metastasis and other indicators). Results The positive expression rate of PARP-1 in breast cancer tissues (63.79%) was significantly higher than that in benign breast diseases (9.09%), P = 0.01. The positive expression rate of PARP-1 in breast cancer specimens with lymph node metastasis (80.00%) was higher than those without lymph node metastasis (51.52%), P = 0.031. Conclusion The expression of PARP-1 in breast cancer is related to lymph node metastasis. The up-regulation of PARP-1 may be related to the malignant biological characteristics of breast cancer, which may have some clinical value for the clinical diagnosis and prognosis of breast cancer.